Physician profile
Robert B Fox
NPI 1538258645
$5,528.39
in general payments reported to CMS, 2019-2025
24 companies · $781 in 2025
The $781 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $971 · 2021: $844 · 2022: $738 · 2023: $419 · 2024: $611 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $757.90 | 2019-2021 | |
| Allergan, INC. | $681.28 | 2019-2022 | |
| Alcon Vision LLC | $645.16 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $615.30 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $354.58 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Abbvie INC. | $352.88 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $341.54 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $331.57 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $288.92 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $207.83 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $194.41 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $112.42 | 2020-2022 | |
| Oyster Point Pharma, INC. | $111.90 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $95.64 | 2019-2022 | |
| Omeros Corporation | $94.04 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $71.04 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Dompe US, INC. | $69.79 | 2024-2025 | Oxervate |
| Shire North American Group INC | $51.96 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $37.61 | 2019-2020 | |
| Ocular Therapeutix, INC. | $26.31 | 2020 | |
| Thea Pharma INC. | $24.00 | 2024 | Iyuzeh |
| Rxsight INC | $21.24 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Abb Con-Cise Optical Group LLC | $21.07 | 2019-2020 | |
| Sight Sciences, INC. | $20.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.